[go: up one dir, main page]

IS8058A - Sýklísk súlfónamíð til að hamla gamma seytiasa - Google Patents

Sýklísk súlfónamíð til að hamla gamma seytiasa

Info

Publication number
IS8058A
IS8058A IS8058A IS8058A IS8058A IS 8058 A IS8058 A IS 8058A IS 8058 A IS8058 A IS 8058A IS 8058 A IS8058 A IS 8058A IS 8058 A IS8058 A IS 8058A
Authority
IS
Iceland
Prior art keywords
gamma secretion
inhibit gamma
cyclic sulfonamide
inhibit
sulfonamide
Prior art date
Application number
IS8058A
Other languages
English (en)
Inventor
Dinnell Kevin
Harrison Timothy
John Nadin Alan
Pate Owens Andrew
Edward Shaw Duncan
John Williams Brian
Original Assignee
Merck Sharp & Dohme Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0311341A external-priority patent/GB0311341D0/en
Priority claimed from GB0327055A external-priority patent/GB0327055D0/en
Application filed by Merck Sharp & Dohme Limited filed Critical Merck Sharp & Dohme Limited
Publication of IS8058A publication Critical patent/IS8058A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/021,2-Thiazines; Hydrogenated 1,2-thiazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
IS8058A 2003-05-16 2005-09-30 Sýklísk súlfónamíð til að hamla gamma seytiasa IS8058A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0311341A GB0311341D0 (en) 2003-05-16 2003-05-16 Therapeutic agents
GB0327055A GB0327055D0 (en) 2003-11-20 2003-11-20 Therapeutic agents
PCT/GB2004/002013 WO2004101539A1 (en) 2003-05-16 2004-05-07 Cyclic sulfonamides for inhibition of gamma-secretase

Publications (1)

Publication Number Publication Date
IS8058A true IS8058A (is) 2005-09-30

Family

ID=33420897

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8058A IS8058A (is) 2003-05-16 2005-09-30 Sýklísk súlfónamíð til að hamla gamma seytiasa

Country Status (16)

Country Link
US (3) US7410964B2 (is)
EP (2) EP1638951B1 (is)
JP (1) JP4818114B2 (is)
KR (1) KR20060013404A (is)
AT (1) ATE386028T1 (is)
AU (1) AU2004238607B2 (is)
BR (1) BRPI0409969A (is)
CA (1) CA2525841C (is)
DE (1) DE602004011767T2 (is)
IL (1) IL171977A (is)
IS (1) IS8058A (is)
MX (1) MXPA05012323A (is)
NO (1) NO20055979L (is)
NZ (1) NZ542797A (is)
RU (1) RU2334743C2 (is)
WO (2) WO2004101538A1 (is)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
EP1638951B1 (en) * 2003-05-16 2008-02-13 MERCK SHARP & DOHME LTD. Cyclohexyl sulphones as gamma-secretase inhibitors
EP1812007B1 (en) 2004-11-02 2011-09-07 Northwestern University Pyridazine compounds and methods
WO2006123183A2 (en) * 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Sulphone derivatives for treatment of cancer
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
GB0512049D0 (en) * 2005-06-14 2005-07-20 Merck Sharp & Dohme Chemical process
AR059075A1 (es) * 2006-01-20 2008-03-12 Schering Corp Bencesulfonil - cromano , tiocromano tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
EP2435416B1 (en) 2007-07-05 2016-03-30 Merck Sharp & Dohme Corp. Tetrahydropyranochromene gamma secretase inhibitors
WO2009011851A1 (en) 2007-07-17 2009-01-22 Schering Corporation Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US20110263580A1 (en) * 2008-12-11 2011-10-27 Thomas Miller Method for treating alzheimer's disease and related conditions
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CN102638981B (zh) 2009-10-14 2015-07-22 默沙东公司 提高p53活性的取代的哌啶和其用途
US20120295923A1 (en) * 2010-01-29 2012-11-22 Pfizer Inc. Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
ES2481823T3 (es) 2010-03-10 2014-07-31 Probiodrug Ag Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
MA53287A (fr) 2018-08-07 2022-05-11 Merck Sharp & Dohme Inhibiteurs de prmt5
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US20230108114A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
CA3160153A1 (en) 2019-12-17 2021-06-24 Michelle Machacek Prmt5 inhibitors
WO2022015670A1 (en) * 2020-07-14 2022-01-20 Nikang Therapeutics, Inc. Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors
CA3265870A1 (en) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Pharmaceutical compositions based on topoisomerase-1 inhibitors derived from Exatecan, and their uses
EP4608453A1 (en) 2022-10-25 2025-09-03 Merck Sharp & Dohme LLC Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
IL321395A (en) 2022-12-14 2025-08-01 Merck Sharp & Dohme Llc Auristatin cargo-linkers, pharmaceutical compounds, and their uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2833776A (en) * 1958-05-06 Aryl-substituted psperidylpropanols
US3992536A (en) * 1972-11-11 1976-11-16 Boehringer Ingelheim Gmbh Pharmaceutical compositions containing a 1-phenyl-2,2,4,4-C1 -C2 alkyl-3-[4-phenyl of pyridyl)-piperazino]-cyclobutanol-(1) and method of use
US3869434A (en) * 1973-11-19 1975-03-04 Phillips Petroleum Co Soluble arylene sulfide polymers
DE2528285A1 (de) * 1975-06-25 1977-01-20 Basf Ag Verfahren zur herstellung von 1,2,4-dihydrotriazin-4-oxid-spiro- (3,1')- eckige klammer auf oximino- (2')-cycloalkanen eckige klammer zu
FR2528433A1 (fr) * 1982-06-15 1983-12-16 Provesan Sa Nouveaux derives d'oxazinobenzothiazine-6,6-dioxyde, leur preparation et leur application en tant que medicaments
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IL133604A0 (en) * 1997-07-16 2001-04-30 Novo Nordisk As Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
PL349781A1 (en) 1999-02-26 2002-09-09 Merck & Co Inc Novel sulfonamide compounds and uses thereof
AU2001240861B2 (en) * 2000-03-20 2006-03-30 Merck Frosst Canada Ltd Sulphonamido-substituted bridged bicycloalkyl derivatives
FR2812291B1 (fr) * 2000-07-28 2002-12-13 Adir Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP3880051B2 (ja) 2000-11-02 2007-02-14 メルク シャープ エンド ドーム リミテッド γ−セクレターゼ阻害剤としてのスルファミド
GB0108592D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
WO2003055850A1 (en) 2001-12-27 2003-07-10 Daiichi Pharmaceutical Co., Ltd. β-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS
EP1638951B1 (en) 2003-05-16 2008-02-13 MERCK SHARP & DOHME LTD. Cyclohexyl sulphones as gamma-secretase inhibitors

Also Published As

Publication number Publication date
RU2334743C2 (ru) 2008-09-27
US7342009B2 (en) 2008-03-11
WO2004101539A1 (en) 2004-11-25
US20040230054A1 (en) 2004-11-18
DE602004011767D1 (de) 2008-03-27
AU2004238607A1 (en) 2004-11-25
IL171977A0 (en) 2006-04-10
DE602004011767T2 (de) 2009-02-19
BRPI0409969A (pt) 2006-04-25
KR20060013404A (ko) 2006-02-09
CA2525841C (en) 2012-10-16
MXPA05012323A (es) 2006-01-30
JP4818114B2 (ja) 2011-11-16
RU2005139398A (ru) 2006-04-10
EP1638951A1 (en) 2006-03-29
IL171977A (en) 2010-12-30
AU2004238607B2 (en) 2010-05-27
ATE386028T1 (de) 2008-03-15
US20060281737A1 (en) 2006-12-14
CA2525841A1 (en) 2004-11-25
EP1644346A1 (en) 2006-04-12
JP2006528961A (ja) 2006-12-28
NZ542797A (en) 2007-12-21
US7410964B2 (en) 2008-08-12
WO2004101538A1 (en) 2004-11-25
NO20055979L (no) 2006-02-15
EP1638951B1 (en) 2008-02-13
US20080045515A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
IS8058A (is) Sýklísk súlfónamíð til að hamla gamma seytiasa
DE60134874D1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
ATE444293T1 (de) Cyclische sulfamide zur inhibierung von gamma- sekretase
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE435219T1 (de) Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
GB0223040D0 (en) Therapeutic compounds
GB0223038D0 (en) Therapeutic compounds
GB0318447D0 (en) Therapeutic agents
GB0225474D0 (en) Therapeutic agents
DE60144064D1 (de) Sulfone, die die aktivität von gamma-secretase modulieren
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
TNSN02022A1 (fr) Triazolopyridines anti-inflammatoires nouvelles, et compositions les contenant
ATE302753T1 (de) Sulfamide als gamma-secretase-inhibitoren
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
DE602006010442D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
ATE446285T1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren
NO20055741L (no) Nye kjemiske forbindelser
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
ATE556053T1 (de) Piperidinderivate zur behandlung von alzheimer- krankheit
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
DE602005018390D1 (de) Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren